India Cancer Diagnostics Market By Product (Instruments, Consumables, Services), By Type (IVD, LDT, Imaging), By Application (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By Test-Type (Biopsy, Others), By End-User (Hospitals, Laboratories, Others), By Region, Competition, Forecast, & Opportunities, 2020-2030F

Market Overview

India Cancer Diagnostics Market was valued at USD 4.56 billion in 2024 and is expected to reach USD 8.12 billion by 2030, growing with a CAGR of 10.21% in the forecast period. 

The cancer diagnostics market in India is witnessing strong growth, driven by lifestyle changes, increasing health awareness, and improving healthcare infrastructure. A growing focus on preventive healthcare and early disease detection is encouraging the adoption of advanced diagnostic solutions across the country. With rising cancer prevalence and delayed diagnoses due to busy lifestyles, there is increasing demand for accurate and accessible testing methods that support early-stage detection and better treatment outcomes.

Higher healthcare spending and continuous investments in medical technologies are accelerating market expansion. The growing network of diagnostic laboratories and the adoption of advanced techniques such as molecular diagnostics, imaging, and biomarker testing are enhancing diagnostic accuracy. Additionally, India’s aging population, which is more prone to cancer, is significantly contributing to demand.

With ongoing technological advancements and increasing awareness, the cancer diagnostics market in India is expected to expand steadily, improving patient outcomes and strengthening the country’s diagnostic capabilities.

Key Market Drivers

Increasing Cancer Incidence

Demographic shifts, lifestyle changes, and environmental factors are collectively driving an unprecedented rise in India's cancer burden.

• India's aging population and demographic shifts have significantly increased the cancer burden, a crisis highlighted in a May 2025 National Academy of Medical Sciences (NAMS) report which noted that inadequate diagnostic infrastructure leads to later-stage disease presentations compared to Western nations, with nearly 200,000 new cases reported annually.

• Rapid urbanization and the adoption of Western dietary habits, characterized by high consumption of processed foods and sedentary lifestyles, are major risk factors, while rising environmental pollution, including exposure to air pollutants, pesticides, and contaminated groundwater from industrialization, further exacerbates the escalating cancer incidence across the country.

• The surging cancer incidence has created profound growth opportunities for the diagnostics market, driving unprecedented demand for screening tests, imaging studies, and laboratory diagnostics, which in turn prompts healthcare providers and market players to heavily invest in research, development, and portfolio expansion to deliver state-of-the-art molecular innovations and precise diagnostic solutions.

Awareness and Early Detection

Increased educational efforts and shifting societal attitudes are significantly improving the rates of early cancer diagnosis across India.

• Intensive awareness campaigns led by NGOs, government bodies, and healthcare institutions are successfully breaking down historical cultural stigmas and taboos associated with cancer, fostering open discussions that shift public behavior toward seeking timely healthcare and participating in early detection programs like breast cancer screening camps and targeted tobacco cessation initiatives.

• Educational initiatives have significantly improved access to vital screening services through the deployment of mobile cancer screening units and specialized diagnostic clinics, ensuring that patients receive early diagnoses which are inherently linked to highly treatable stages, complete remission possibilities, and vastly improved overall survival rates.

• Heightened awareness has catalyzed a massive surge in demand for specialized screening infrastructure, driving the development of highly sensitive procedures like liquid biopsies that detect circulating tumor DNA, while prompting diagnostic providers to strategically collaborate with healthcare organizations to acquire state-of-the-art imaging equipment and skilled personnel to meet escalating public needs.

Advancements in Technology

Rapid technological integration is transforming the accuracy, efficiency, and accessibility of the cancer diagnostics market.

• The landscape of medical imaging has been transformed by high-resolution modalities like MRI, CT, and PET scans, complemented by major regulatory milestones such as the April 2025 FDA clearance awarded to Indian company Unimeditrek Pvt. Ltd. for its complete line of histopathology laboratory equipment, significantly validating and elevating the country's diagnostic standards.

• Groundbreaking molecular diagnostics, including Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), allow healthcare providers to analyze genetic markers for personalized therapies, while non-invasive liquid biopsies that detect circulating tumor DNA provide a revolutionary, minimally invasive method for identifying early-stage malignancies and continuously monitoring a patient's response to targeted treatments.

• The rapid integration of artificial intelligence and machine learning algorithms reduces human error in pathology reports, while the pandemic-driven acceleration of telemedicine and portable point-of-care testing devices ensures that patients in remote or underserved areas receive rapid biomarker evaluations, faster turnaround times, and prompt initiation of lifesaving medical interventions.

Government Initiatives

Comprehensive state-sponsored programs and infrastructure investments are dramatically enhancing nationwide access to vital cancer care.

• The National Cancer Control Program (NCCP) serves as the cornerstone of India's strategic fight against the disease by comprehensively supporting prevention, early detection, and palliative care, while heavily investing in upgrading critical healthcare infrastructure, including the construction of advanced cancer hospitals and state-of-the-art radiation therapy centers to ensure equitable patient access.

• Innovative grassroots initiatives are expanding diagnostic reach into underserved communities, exemplified by a June 2025 deployment of a mobile cancer-detecting van in rural Pune equipped with modern screening tools and trained medical professionals, playing a pivotal role in identifying early-stage malignancies among villagers with limited access to traditional healthcare facilities.

• Government agencies are aggressively conducting extensive public awareness campaigns to educate citizens about risk factors and symptoms, while simultaneously fostering advanced medical research and funding specialized training programs for healthcare professionals to vastly improve national cancer management capabilities and drive the continuous evolution of cutting-edge diagnostic methodologies.

National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS)

This comprehensive framework integrates cancer management into a broader public health strategy targeting non-communicable diseases.

• The NPCDCS adopts a highly integrated approach to healthcare by embedding cancer control within a broader strategy for managing non-communicable diseases, providing critical financial support directly to state governments to seamlessly implement extensive screening activities, comprehensive treatment services, and robust infrastructural upgrades across diagnostic labs and radiology facilities.

• To sustain long-term market growth and ensure inclusive healthcare, the program prioritizes equipping frontline healthcare workers with specialized diagnostic skills while actively encouraging mutually beneficial collaborations between public agencies and private diagnostic companies to supply advanced testing equipment, streamline service delivery, and expand testing access to marginalized demographic groups.

• Government-backed research grants and financial incentives provided under these comprehensive initiatives not only deepen the medical community's understanding of complex oncological diseases but also fuel rapid technological innovation within the private sector, resulting in a more robust, competitive diagnostics market that effectively addresses the surging national demand for early cancer screenings.

Key Market Challenges

Limited Healthcare Infrastructure

• Advanced cancer diagnostic capabilities, including comprehensive imaging, biopsy, histopathology, and molecular testing, remain heavily concentrated in major metropolitan centers, forcing rural patients to navigate severely fragmented referral networks and travel extensive distances, which significantly increases initial costs and drastically delays critical specialist oncology interventions.

• Beyond the sheer scarcity of medical facilities, low-resource districts suffer from profound structural constraints, including widespread equipment shortages, a lack of specialized personnel, and poorly coordinated diagnostic pathways, which inherently reduce the effective reach of early screening and contribute to adverse late-stage disease presentations.

• The capacity for accessible district-level cancer care is still in a developmental phase across India, as evidenced by the national NP-NCD programme, which has established 770 District NCD Clinics, 364 District Day Care Cancer Centres, and 6,410 Community Health Centre level NCD clinics to combat these severe infrastructure gaps.

High Cost of Diagnostic Procedures

• Securing a definitive cancer diagnosis involves navigating multiple inherently expensive clinical touchpoints, such as advanced imaging scans, complex biopsies, immunohistochemistry, specialized biomarker testing, and repeat specialist consultations, creating formidable financial barriers that routinely discourage early clinical screening for households lacking comprehensive health insurance coverage.

• Financial pressures are particularly devastating for lower-income and semi-urban populations, where the compounding economic burdens of travel expenses, accommodation costs, lost daily wages, and repeated hospital visits are added directly to medical bills, making advanced diagnostic protocols appear completely unmanageable and inaccessible.

• When patients postpone necessary medical testing due to severe affordability concerns, diagnoses inevitably shift to later and more dangerous stages, a reality underscored by a multicentre Indian study of 12,148 patients showing an annual out-of-pocket expenditure of ₹331,177, with diagnostics comprising 36.4% of outpatient spending.

Lack of Awareness and Stigma

• Pervasive social stigma and a fundamental lack of awareness critically hinder the diagnostics market, as widespread fear, deep-rooted embarrassment, and fatalistic cultural misconceptions deter individuals from seeking early screening for breast, cervical, and oral cancers, even when public programs offer these services at a relatively low cost.

• Insufficient public education severely weakens patient follow-through after the initial onset of alarming physical symptoms, causing suspicious and potentially highly treatable malignancies to remain entirely undiagnosed until the disease aggressively progresses to advanced stages that require significantly more complex and financially draining medical interventions.

• The devastating impact of this awareness deficit on market penetration and public health is starkly illustrated by epidemiological analysis of NFHS-5 data, which revealed exceptionally low national participation rates of just 1.2% for cervical cancer screening, 0.6% for oral cancer screening, and 0.5% for breast cancer screening.

Key Market Trends

Rise in Personalized Medicine and Targeted Therapies

• Personalized medicine and targeted therapies have gained prominence in cancer diagnostics and treatment. Advancements in molecular diagnostics and genomic profiling have allowed healthcare providers to tailor cancer therapies to the specific genetic characteristics of a patient's tumor. This trend is increasingly shaping the landscape of cancer diagnostics in India.

• The adoption of personalized medicine not only improves treatment outcomes but also drives the demand for advanced diagnostic tests that identify specific biomarkers and genetic mutations. Diagnostic companies are developing tests that help oncologists select the most effective treatments for individual patients, leading to increased market growth. Liquid biopsies, which detect circulating tumor DNA, are gaining traction for monitoring treatment response and identifying resistance mutations. The companion diagnostics are becoming more common, guiding the use of targeted therapies.

Telemedicine and Remote Consultations

• The COVID-19 pandemic accelerated the adoption of telemedicine and remote consultations in healthcare, including cancer diagnostics. Telemedicine platforms and virtual consultations with oncologists have become more accessible and accepted by patients, particularly those in remote or underserved areas.

• Telemedicine has expanded the reach of cancer diagnostic services, allowing individuals to consult with specialists without the need for long-distance travel. This trend enhances early detection by ensuring that individuals from all geographical locations can access diagnostic consultations and recommendations. Tele-oncology services provide expert opinions and guidance for cancer diagnostics, treatment planning, and follow-up care. Patients can undergo initial consultations and receive test results remotely, improving the overall patient experience.

Artificial Intelligence (AI) and Machine Learning Integration

• The integration of artificial intelligence (AI) and machine learning (ML) into cancer diagnostics is a growing trend in India. These technologies analyze vast datasets, including medical images and pathology reports, to assist radiologists and pathologists in diagnosing cancer more accurately and efficiently.

• AI and ML algorithms can detect subtle patterns and anomalies in medical images, improving the accuracy of cancer diagnoses. They assist in risk prediction, early detection, and treatment planning. The adoption of AI-driven diagnostic tools is enhancing the capabilities of healthcare professionals and driving market growth. AI-powered software can assist in mammography interpretations, lung nodule detection in CT scans, and the analysis of histopathological slides. These tools expedite the diagnostic process and reduce the risk of human error.

Segmental Insights

Product Insights

Based on product, The consumables segment emerged as the fastest-growing segment in the India cancer diagnostics market, fueled by the rising demand for cancer diagnostic reagents. These reagents are essential for key diagnostic techniques such as immunohistochemistry (IHC), in situ hybridization (ISH), and molecular diagnostics tests, all of which are crucial for the precise detection and classification of cancer.

The escalating prevalence of cancer in India has intensified the demand for advanced and reliable testing solutions, significantly boosting the consumption of consumables in diagnostic procedures. A major driver of this growth is the increasing awareness about the benefits of early cancer detection, which greatly improves patient outcomes and treatment success rates. As both patients and healthcare professionals adopt a more proactive approach to early diagnosis, the reliance on high-quality consumables continues to expand.

Additionally, government initiatives and private sector investments are strengthening diagnostic infrastructure and accelerating innovation in test development. These efforts not only enhance the accessibility of cancer diagnostic services but also foster the introduction of next-generation consumables tailored to evolving clinical needs. Together, these factors are positioning consumables as the fastest-growing segment in India’s cancer diagnostics landscape.

Type Insight

Based on type, in 2024, the in vitro diagnostics (IVD) segment emerged as the leading force in India’s cancer diagnostics market, driven by its broad applicability, growing affordability, and increasing availability across healthcare settings. IVD cancer diagnostic tests, including immunohistochemistry (IHC), in situ hybridization (ISH), and molecular diagnostics, are widely used in hospitals and diagnostic labs for detecting, classifying, and monitoring various types of cancer.

These tests are known for their precision, reliability, and ability to support early detection, making them integral to cancer care protocols. One of the key factors behind the segment’s dominance is the cost-effectiveness of IVD tests compared to more complex or infrastructure-intensive methods like laboratory-developed tests (LDTs) and advanced imaging techniques. This affordability makes IVD tests more accessible to a broader patient population, especially in tier 2 and tier 3 cities where affordability and accessibility are key concerns.

The increased government funding and private sector investments have led to the development and expansion of cancer diagnostic infrastructure in India. As diagnostic laboratories and healthcare providers adopt modern testing platforms, the availability and reach of IVD tests have grown significantly. These factors, combined with the rising cancer burden and public health initiatives promoting early screening, are expected to sustain the IVD segment’s strong performance in the years ahead.

Application Insight

Based on application, in 2024, the breast cancer segment emerged as the dominant player in India’s cancer diagnostics market, largely due to the high prevalence of breast cancer among women. As per the National Cancer Registry, breast cancer accounted for approximately 29% of all cancer cases in Indian women, making it the most common form of cancer affecting the female population.

This high incidence has significantly increased the demand for early detection and effective diagnostic solutions. Early diagnosis of breast cancer is critical to improving survival rates and treatment outcomes. With growing awareness campaigns, both public and private, more women are now seeking regular screenings and check-ups. This shift in behavior has driven the uptake of diagnostic tests such as mammography, ultrasound, biopsy, and molecular diagnostics tailored for breast cancer detection. Government initiatives like Ayushman Bharat and targeted screening programs have increased funding and accessibility to diagnostic services.

Simultaneously, the private sector is actively investing in expanding diagnostic infrastructure and innovating new technologies, including portable screening tools and AI-enabled diagnostics. These combined efforts are making breast cancer diagnostics more available, affordable, and efficient, thereby reinforcing the segment's leading position in India’s cancer diagnostics landscape.

Download Free Sample Report

Regional Insights

North India Segment emerged as the dominant region in the India Cancer Diagnostics market in 2024, holding the largest market share in terms of value. North India, particularly the National Capital Region (NCR) and major cities like Delhi, has historically had a more advanced healthcare infrastructure compared to other regions. The presence of top-tier hospitals, cancer centers, and diagnostic laboratories in these areas has contributed to the dominance of North India in the cancer diagnostics market. Patients from neighbouring states often travel to North India for specialized diagnostic services. North India hosts a significant concentration of leading healthcare institutions, research centers, and medical colleges.

These institutions often serve as hubs for cancer diagnosis, research, and treatment. Their expertise and state-of-the-art diagnostic facilities attract patients from across the country. North India, including the NCR, has a relatively higher population density compared to many other regions. The larger population base translates to a higher number of potential patients seeking cancer diagnostic services. This factor contributes to the dominance of North India in terms of market size. North India, particularly urban areas, has relatively higher awareness levels about cancer and the importance of early detection.

The population in these areas often has better access to healthcare insurance and financial resources, making them more likely to afford advanced diagnostic tests. Leading medical institutions and research centers in North India actively engage in cancer research and diagnostic innovation. This environment fosters the development and adoption of cutting-edge diagnostic technologies, further strengthening the region's dominance in the market.

Recent Developments

• In April 2025, Molbio Diagnostics unveiled Truenat HPV-HR Plus, an upgraded chip-based RT-PCR test for cervical cancer screening that detects eight high-risk HPV genotypes linked to more than 96 percent of cervical cancer cases globally. The test was designed for rapid, decentralized use, delivers results in about 60 minutes, and was clinically validated through a multicentric program supported by Grand Challenges India, BIRAC, and the Department of Biotechnology, giving it strong institutional backing in India’s cancer diagnostics ecosystem.

• In May 2025, Mahajan Imaging & Labs launched north India’s first technology-driven cancer diagnostics laboratory in Gurugram, centered on a 128-slice digital PET-CT scanner with AI-powered imaging. News reports said the new setup can reduce radiation exposure by up to 60 percent while enabling faster scans, sharper image quality, and integrated pathology support, making it a notable breakthrough in technology-led early cancer detection in India.

• In June 2025, Tata Memorial Centre signed an MoU with Wipro GE HealthCare to establish a Cancer Research and Innovation Centre in India focused on precision-led oncology supported by imaging, AI, and digital platforms. Under the collaboration, Tata Memorial Centre became the clinical oncology partner while Wipro GE HealthCare took the technology role, with the center set to work on AI-powered applications for medical imaging and diagnostics, image post-processing, clinical workflow tools, and annotated datasets for research and validation.

• In September 2025, IndiaAI and the National Cancer Grid launched the Cancer AI & Technology Challenge, or CATCH, to support the development and deployment of AI solutions for cancer screening, diagnostics, treatment support, and healthcare operations across India. The program offers up to Rs 50 lakh per selected project, with possible scale-up support of up to Rs 1 crore, and is intended to pilot clinically deployable diagnostic innovations within the National Cancer Grid hospital network.

• In July 2025, Bengaluru: Scientists from the Indian Institute of Science (IISc) developed a simple, glowing paper sensor that could help detect liver cancer at an early stage. The sensor used the green glow of a rare earth metal called terbium to indicate the presence of cancer markers. This innovation aimed to make early liver cancer detection more accessible and affordable through a lightweight, easy-to-use tool.

• In July 2025, the impact of artificial intelligence on health care—from cancer detection to treatment—was explored in depth. AI had already begun transforming the very fabric of the medical field, offering the promise of a 'healthier human'. This marked the second part of a three-part series that examined how AI technologies had reshaped diagnostics, personalized treatment, and overall patient care across various healthcare settings.

Key Market Players

• Baxter Pharmaceuticals India Private Limited.
• Bristol-Myers Squibb India Private Limited.
• Cipla Ltd.
• Roche Products (India) Private Limited.
• Glenmark Pharmaceuticals Ltd.
• Lupin Ltd
• Abbott India Laboratories Limited
• BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
• Siemens Healthcare Private Limited.
• Thermo Fisher Scientific India Private Limited.

Report Scope:

In this report, the India Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Cancer Diagnostics Market, By Product:

o   Instruments

o   Consumables

o   Services

• India Cancer Diagnostics Market, By Type:

o   IVD

o   LDT

o   Imaging

• India Cancer Diagnostics Market, By Application:

o   Breast Cancer

o   Colorectal Cancer

o   Cervical Cancer

o   Lung Cancer

o   Prostate Cancer

o   Skin Cancer

o   Blood Cancer

o   Kidney Cancer

o   Liver Cancer

o   Pancreatic Cancer

o   Ovarian Cancer

o   Others

• India Cancer Diagnostics Market, By Test-Type:

o   Biopsy

o   Others

• India Cancer Diagnostics Market, By End-User:

o   Hospitals

o   Laboratories

o   Others

• India Cancer Diagnostics Market, By Region:

o   North India

o   South India

o   East India

o   West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Cancer Diagnostics Market.

Available Customizations:

India Cancer Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Cancer Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]